Literature DB >> 10460103

Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids.

C A Peloquin1, R Namdar, A A Dodge, D E Nix.   

Abstract

STUDY
OBJECTIVES: To determine the intra- and intersubject variability in and the effects of food or antacids on the pharmacokinetics of isoniazid (INH).
DESIGN: Randomized, four-period cross-over Phase I study in 14 healthy male and female volunteers. Subjects ingested single doses of INH 300 mg under fasting conditions twice, with a high-fat meal, and with aluminum-magnesium antacid. They also received standard doses of rifampin, pyrazinamide, and ethambutol.
RESULTS: Serum was collected for 48 hours, and assayed by high performance liquid chromatography (HPLC). Data were analyzed using noncompartmental methods and a compartmental analysis using nonparametric expectation maximization. Both fasting conditions produced similar results: a mean INH Cmax of 5.53 +/- 2.92 microg/ml, Tmax of 1.02 +/- 1.10 hours, and AUC0-infinity of 20.16 +/- 12.45 microg x hr/ml. These findings are similar to those reported previously. Antacids did not alter these parameters significantly (Cmax of 5.62 +/- 2.53 microg/ml, Tmax of 0.71 +/- 0.56 hours, and AUC0-infinity of 20.27 +/- 11.39 microg x hr/ml). In contrast, the high-fat meal recommended by the Food and Drug Administration reduced INH Cmax by 51% (2.73 +/- 1.70 microg/ml), nearly doubled Tmax (1.93 +/- 1.61 hours), and reduced AUC0-infinity by 12% (17.72 +/- 10.32 microg x hr/ml).
CONCLUSIONS: These changes in Cmax, Tmax, and AUC0-infinity can be avoided by giving INH on an empty stomach whenever possible.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10460103

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  27 in total

1.  Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids.

Authors:  B Auclair; D E Nix; R D Adam; G T James; C A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  Food-drug interactions.

Authors:  Lars E Schmidt; Kim Dalhoff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.

Authors:  L Lalande; L Bourguignon; S Bihari; P Maire; M Neely; R Jelliffe; S Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

5.  Reply to "adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future".

Authors:  Ana Requena-Méndez; Geraint Davies; David A J Moore
Journal:  Antimicrob Agents Chemother       Date:  2015-04       Impact factor: 5.191

Review 6.  Clinically significant drug interactions with antacids: an update.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

Review 7.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

8.  Induction of protective autophagy against apoptosis in HepG2 cells by isoniazid independent of the p38 signaling pathway.

Authors:  Tian-Guang Zhang; Yi-Mei Wang; Jun Zhao; Ming-Yu Xia; Shuang-Qing Peng; Takashi Ikejima
Journal:  Toxicol Res (Camb)       Date:  2016-04-04       Impact factor: 3.524

Review 9.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

10.  Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid.

Authors:  John E Conte; Jeffrey A Golden; Mari McQuitty; Juliana Kipps; Sheila Duncan; Elaine McKenna; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.